This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Wolf Haldenstein Announces Investigation Of Acquisition Of Santarus, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) is investigating the acquisition of Santarus, Inc. (NASDAQ: SNTS) by Salix Pharmaceuticals Ltd. Santarus and Salix Pharmaceuticals announced that the companies have entered into a definitive agreement whereby Salix Pharmaceuticals will acquire Santarus for $32.00 per share in a cash tender offer. We believe that this offer significantly undervalues the Company and that there were deficiencies in the sale process.

The investigation concerns whether the Santarus board of directors breached their fiduciary duties by failing to engage in a full and fair process to ensure maximum value for the shareholders. Indeed, Santarus reported impressive financial and operating results for the quarter and nine months ended September 30, 2013, including a 81% increase in revenue from the third quarter of 2012 and net income of $30.3 million, or $0.38 diluted earnings per share (EPS), compared with $9.0 million, or $0.13 diluted EPS for the third quarter of 2012. Moreover, certain directors and officers of Santarus, who owned approximately 12 percent of the outstanding stock, have agreed to tender their shares in the offer and vote against any competing bids to acquire Santarus.

Wolf Haldenstein believes that the Santarus board of directors may have breached their fiduciary duties to shareholders by: (1) conducting an inadequate sales process and (2) by failing to maximize shareholder value.

Wolf Haldenstein, currently celebrating its 125 th year of providing exemplary services to its clients, has represented individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm and its attorneys.

If you are a shareholder of Santarus Inc. (NASDAQ: SNTS) and would like additional information as to how the acquisition may affect your rights as a shareholder, please contact us at:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs